Clinical trials: Amplification
FLT3-ITD Mutation, FLT3/TKD Mutation
Individual Patient Compassionate Use of Crenolanib
Compassionate use of crenolanib for patients with serious life-threatening illness that have exhausted all available therapies used to treat the disease, with no other viable therapy options, who is not eligible for clinical…
- Conditions
- FLT3-ITD Mutation, FLT3/TKD Mutation, PDGFR-Alpha D842V, PDGFRA Gene Amplification
- Trial name
- NCT03620318
- Testing
- Crenolanib besylate
- Where
- Italy
- Sponsor
- Arog Pharmaceuticals, Inc.
Chlamydia Infections, Gonorrhea
Nucleic Acid Amplification Tests (NAATs) for the Diagnosis of Pharyngeal and Rectal Chlamydia and Gonorrhea Infections
Investigators at the University of Alabama in Birmingham in collaboration with investigators from the Centers for Disease Control in Atlanta are evaluating the performance of three commercial nucleic acid amplification tests for…
- Trial name
- NCT00252096
- Testing
- Nucleic acid amplification test
- Where
- United States
- Volunteers
- 3,900 people
- Sponsor
- Centers for Disease Control and Prevention
Breast Neoplasms, HER-2 Gene Amplification
Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer
This retrospective study evaluated the efficacy and the safety of use of this treatment combined with a taxane for the treatment of HER2-positive metastatic breast cancer and compared the clinical and demographic characteristics…
- Trial name
- EPTTCSM (NCT03979911)
- Where
- France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Brest
Solid Tumors Harboring MET Amplification
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan.
- Trial name
- NCT07196644
- Testing
- Telisotuzumab Adizutecan
- Where
- 38 sites in United States, Israel and 3 more
- Volunteers
- 100 people
- Sponsor
- AbbVie
Hearing Loss, Children With Hearing Differences
Assessing Speech Perception and Amplification Benefit During Infancy
The goal of this project is to compare aided and unaided speech discrimination among infants with hearing loss and a cohort of infants with typical hearing.
- Conditions
- Hearing Loss, Children With Hearing Differences, Amplification, Speech Perception
- Trial name
- NCT05653999
- Testing
- Hearing Aids
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Melanoma, Solid Tumor
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions…
- Conditions
- Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification
- Trial name
- NCT04985604
- Testing
- Tovorafenib
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification
Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer
Microlyvaq™ is a first-line, non-randomized, two-arm clinical trial in advanced non-small cell lung cancer (NSCLC). In both arms, patients receive a personalized multi-epitope vaccine (Microlyvaq™) on top of standard-of-care…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer
- Trial name
- Microlyvaq™ (NCT07285434)
- Testing
- Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic)
- Where
- Greece
- Volunteers
- 90 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Advanced Gastric Adenocarcinoma
Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment
Phase Ib/II, single-arm study of AZD6094 (Volitinib) in combination with docetaxel, in advanced gastric adenocarcinoma patients with MET amplification as a second-line treatment.
- Trial name
- NCT02447406
- Testing
- AZD6094, docetaxel
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Samsung Medical Center
Cutaneous Leishmaniasis (Diagnosis)
Performance of RPA-LF for Cutaneous Leishmaniasis
CL is public health in the Americas, diagnostic confirmation is required to start treatment, however current diagnostic methods have several limitations and its access is limited.
- Trial name
- RPA-LF (NCT04500873)
- Where
- Colombia
- Volunteers
- 128 people
- Sponsor
- Centro Internacional de Entrenamiento e Investigaciones Médicas
Haematological Malignancy, Colorectal Neoplasms
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other…
- Conditions
- Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms
- Trial name
- DETERMINE (NCT05786716)
- Testing
- Trastuzumab, Pertuzumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease
Persons living with HIV (PLWH) in sub-Saharan Africa (SSA), lymphadenopathy often portends one of a number of life-threatening diseases including tuberculosis, lymphoma, and multicentric Castleman disease (MCD).
- Conditions
- HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT07793006
- Testing
- Lymph Node or Core Needle Biopsy, Fine Needle Aspiration, Tiny Isothermal Nucleic acid Amplification System (TINY)
- Where
- Malawi
- Volunteers
- 500 people
- Sponsor
- Indiana University
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
This phase II trial studies the effect of larotrectinib in treating patients with NTRK gene amplification positive solid tumors that have spread to nearby tissues or lymph nodes (locally advanced) or other places in the body…
- Trial name
- NCT04879121
- Testing
- Larotrectinib Sulfate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
A Pilot Study on ALK Gene Mutations in Neuroblastoma
Neuroblastoma (NB) originates from the sympathetic nervous system and is one of the most common cancers in infants and children.
- Trial name
- NCT01986595
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Acute HIV Infection
Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection
The investigators propose to study the impact of nucleic acid amplification testing (NAT) screening for acute Human Immunodeficiency Virus (HIV) and Hepatitis C (HCV) infections and Less-Sensitive Enzyme linked Immunoassay…
- Trial name
- NCT01434706
- Testing
- Nucleic Acid Amplification Testing
- Where
- 5 sites in United States
- Volunteers
- 22,607 people
- Sponsor
- University of California, San Diego
Tuberculosis Diagnosis
Evaluation of New TB Diagnostic Tests (NATs) in Pakistan
This study evaluates two portable molecular tests for tuberculosis (TB), Pluslife MTBC and Ustar PortNAT, during community-based active case-finding activities in Pakistan.
- Trial name
- TB (NCT06984887)
- Testing
- Paired tongue-swab and sputum-based molecular testing for tuberculosis
- Where
- 2 sites in Pakistan
- Volunteers
- 6,100 people, healthy volunteers welcome
- Sponsor
- Mercy Corps Pakistan
Yaws
Evaluation of a LAMP Assay for T. Pallidum. Pertenue
This is a diagnostic evaluation comparing the performance of real-time PCR performed at a national reference laboratory and a LAMP assay performed at a regional hospital for the diagnosis of yaws
- Trial name
- LAMP4YAWS (NCT04753788)
- Testing
- PCR, LAMP
- Where
- 3 sites in Cameroon, Côte d’Ivoire and 1 more
- Volunteers
- 563 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Cervical Cancers, Papillomavirus Infections
Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)
The aim of this retrospective, single-center, observational study is to improve the diagnosis and interpretation of cervical cancer by better detection of epithelial lesions in the case of a late HPV PCR amplification signal…
- Conditions
- Cervical Cancers, Papillomavirus Infections, Papillomavirus Type 16/18 Infection
- Trial name
- PaPCR (NCT06919627)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Brest
Unilateral Hearing Loss
Use of Amplification in Children With Unilateral Hearing Loss
Unilateral hearing loss (UHL) in children has been demonstrated to have a negative impact on quality of life, school performance and behavior. Despite this knowledge, it remains unclear how to best manage this common problem.
- Trial name
- UHL (NCT02269124)
- Testing
- Hearing aid
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Hereditary Diseases
Cell-based Non-invasive Prenatal Testing as an Alternative to Invasive Chorionic Villus Sampling
The study aims to evaluate cell-based non-invasive prenatal testing (cbNIPT) as an alternative to invasive chorionic villus sampling (CVS) in patients who achieve pregnancy following preimplantation genetic testing for hereditary…
- Trial name
- NCT05453474
- Testing
- Whole genome amplification
- Where
- Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Aalborg University Hospital
Anaplastic Astrocytoma, Anaplastic Ependymoma
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma
- Trial name
- NCT03434262
- Testing
- Gemcitabine, ribociclib, sonidegib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- St. Jude Children's Research Hospital